201 related articles for article (PubMed ID: 18516627)
21. Inherited WT1 mutation in Denys-Drash syndrome.
Coppes MJ; Liefers GJ; Higuchi M; Zinn AB; Balfe JW; Williams BR
Cancer Res; 1992 Nov; 52(21):6125-8. PubMed ID: 1327525
[TBL] [Abstract][Full Text] [Related]
22. RNA expression of the WT1 gene in Wilms' tumors in relation to histology.
Miwa H; Tomlinson GE; Timmons CF; Huff V; Cohn SL; Strong LC; Saunders GF
J Natl Cancer Inst; 1992 Feb; 84(3):181-7. PubMed ID: 1311774
[TBL] [Abstract][Full Text] [Related]
23. Regulation of renal EGF receptor expression is normal in Denys-Drash syndrome.
Vicanek C; Ferretti E; Goodyer C; Torban E; Moffett P; Pelletier J; Goodyer P
Kidney Int; 1997 Sep; 52(3):614-9. PubMed ID: 9291179
[TBL] [Abstract][Full Text] [Related]
24. A point mutation found in the WT1 gene in a sporadic Wilms' tumor without genitourinary abnormalities is identical with the most frequent point mutation in Denys-Drash syndrome.
Akasaka Y; Kikuchi H; Nagai T; Hiraoka N; Kato S; Hata J
FEBS Lett; 1993 Feb; 317(1-2):39-43. PubMed ID: 8381368
[TBL] [Abstract][Full Text] [Related]
25. A novel insertional mutation at the third zinc finger coding region of the WT1 gene in Denys-Drash syndrome.
Ogawa O; Eccles MR; Yun K; Mueller RF; Holdaway MD; Reeve AE
Hum Mol Genet; 1993 Feb; 2(2):203-4. PubMed ID: 8098976
[No Abstract] [Full Text] [Related]
26. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor.
Shibata R; Takata A; Hashiguchi A; Umezawa A; Yamada T; Hata J
Pathol Int; 2003 Apr; 53(4):214-20. PubMed ID: 12675764
[TBL] [Abstract][Full Text] [Related]
27. Spectrum of early onset nephrotic syndrome associated with WT1 missense mutations.
Schumacher V; Schärer K; Wühl E; Altrogge H; Bonzel KE; Guschmann M; Neuhaus TJ; Pollastro RM; Kuwertz-Bröking E; Bulla M; Tondera AM; Mundel P; Helmchen U; Waldherr R; Weirich A; Royer-Pokora B
Kidney Int; 1998 Jun; 53(6):1594-600. PubMed ID: 9607189
[TBL] [Abstract][Full Text] [Related]
28. [Wilms' tumors and malformation complexes].
Hata J; Fukuzawa R; Takata A; Kikuchi H
Nihon Rinsho; 2000 Jul; 58(7):1419-25. PubMed ID: 10921316
[TBL] [Abstract][Full Text] [Related]
29. Germline WT1 mutations in Wilms' tumor patients: preliminary results.
Li FP; Breslow NE; Morgan JM; Ghahremani M; Miller GA; Grundy PE; Green DM; Diller LR; Pelletier J
Med Pediatr Oncol; 1996 Nov; 27(5):404-7. PubMed ID: 8827066
[TBL] [Abstract][Full Text] [Related]
30. Atypical clinical presentation of a WT1-related syndrome associated with a novel exon 6 gene mutation.
Dattolo P; Allinovi M; Iatropoulos P; Michelassi S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23715837
[TBL] [Abstract][Full Text] [Related]
31. Nephropathy with Wilms tumour or gonadal dysgenesis: incomplete Denys-Drash syndrome or separate diseases?
Schmitt K; Zabel B; Tulzer G; Eitelberger F; Pelletier J
Eur J Pediatr; 1995 Jul; 154(7):577-81. PubMed ID: 7556327
[TBL] [Abstract][Full Text] [Related]
32. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
33. Genotype/phenotype correlations in Wilms' tumor.
Huff V
Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
[TBL] [Abstract][Full Text] [Related]
34. Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations.
Chernin G; Vega-Warner V; Schoeb DS; Heeringa SF; Ovunc B; Saisawat P; Cleper R; Ozaltin F; Hildebrandt F;
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1655-62. PubMed ID: 20595692
[TBL] [Abstract][Full Text] [Related]
35. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome.
Baird PN; Santos A; Groves N; Jadresic L; Cowell JK
Hum Mol Genet; 1992 Aug; 1(5):301-5. PubMed ID: 1338906
[TBL] [Abstract][Full Text] [Related]
36. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
37. Convergent evolution of 11p allelic loss in multifocal Wilms tumors arising in WT1 mutation carriers.
Valind A; Wessman S; Pal N; Karlsson J; Jonson T; Sandstedt B; Gisselsson D
Pediatr Blood Cancer; 2018 Nov; 65(11):e27301. PubMed ID: 29968962
[TBL] [Abstract][Full Text] [Related]
38. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion.
Little MH; Williamson KA; Mannens M; Kelsey A; Gosden C; Hastie ND; van Heyningen V
Hum Mol Genet; 1993 Mar; 2(3):259-64. PubMed ID: 8388765
[TBL] [Abstract][Full Text] [Related]
39. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
40. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
